95
Participants
Start Date
January 31, 2016
Primary Completion Date
January 31, 2021
Study Completion Date
January 31, 2021
Margetuximab 10 mg/kg
Margetuximab treatment is administered intravenously (IV) once every 21-day cycle
Margetuximab 15 mg
Margetuximab treatment is administered IV once every 21-day cycle
Pembrolizumab
Pembrolizumab treatment is administered IV once every 21-day cycle
Fox Chase Cancer Center, Philadelphia
Georgetown University-Lombardi Comprehensive Cancer Center, Washington D.C.
Johns Hopkins University Medical Center, Baltimore
Gachon University Gil Medical Center, Incheon
Duke University Medical Center, Durham
Sarah Cannon Research Institute, Nashville
Kyungbuk National University Hospital, Daegu
Karmanos Cancer Institute, Detroit
Chonbuk National University Hospital, Seoul
University of Chicago, Chicago
Washington University School of Medicine, St Louis
Swedish Cancer Institute, Seattle
Yale School of Medicine, New Haven
Dana-Farber Cancer Institute/Harvard University Medical Center, Boston
Juravinski Cancer Centre - McMaster University, Hamilton
McGill University Health Centre, Montreal
National Cancer Centre, Singapore
National University Hospital, Singapore
Raffles Hospital, Singapore
Asan Medical Center, Seoul
Korea University Anam Hospital, Seoul
Korea University Guro Hospital, Seoul
Samsung Medical Center, Seoul
Seoul National University Bundang Hospital, Seoul
Seoul National University Hospital, Seoul
National Taiwan University Hospital, Taipei
Taipei Veterans General Hospital, Taipei
Tri-Service General Hospital, Taipei
Lead Sponsor
Merck Sharp & Dohme LLC
INDUSTRY
MacroGenics
INDUSTRY